Sex Differences in the Genetic Predictors of Alzheimer’s Pathology

Logan Dumitrescu, PhD1,2; Lisa L. Barnes, PhD3; Madhav Thambisetty, MD, PhD4; Gary Beecham, PhD5,6; Brian Kunkle, PhD, MPH6; William S. Bush, PhD2; Katherine A. Gifford, PsyD1; Lori B. Chibnik, PhD8,9; Shubhabrata Mukherjee, PhD10; Philip L. De Jager, MD, PhD11,12; Walter Kukull, PhD13; Paul K. Crane, MD10; Susan M. Resnick, PhD4; C. Dirk Keene, MD, PhD14; Thomas J. Montine, MD, PhD15; Gerard D. Schellenberg, PhD16; Yuetiva Deming, PhD17; Michael J. Chao, PhD18; Matt Huentelman, PhD19; Eden R. Martin, PhD5,6; Kara Hamilton-Nelson, MPH6; Leslie M. Shaw, PhD16; John Q. Trojanowski, MD, PhD16; Elaine R. Peskind, MD20; Carlos Cruchaga, PhD17; Margaret A. Pericak-Vance, PhD6; Alison M. Goate, D.Phil18; Nancy J. Cox, PhD2; Jonathan L. Haines, PhD7; Henrik Zetterberg, MD, PhD21,24; Kaj Blennow, MD, PhD21,22; Eric B. Larson, MD, MPH10,25; Sterling C. Johnson, PhD26; Marilyn Albert, PhD27; for the Alzheimer’s Disease Genetics Consortium and the Alzheimer Disease Neuroimaging Initiative2; David A. Bennett, MD3; Julie A. Schneider, MD3; Angela L. Jefferson, PhD1; Timothy J. Hohman, PhD1,2

1Vanderbilt Memory and Alzheimer’s Center, Vanderbilt University Medical Center, Nashville, TN
2Vanderbilt Genetics Institute, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
3Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL
4Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD
5John T MacDonald Foundation Department of Human Genetics, University of Miami, Miami, FL
6John P. Hussman Institute for Human Genomics, University of Miami School of Medicine, Miami, FL
7Department of Population & Quantitative Health Sciences, Institute for Computational Biology, Case Western Reserve University, Cleveland, OH
8Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
9Channing Division of Network Medicine, Brigham & Women’s Hospital, Boston, MA
10Department of Medicine, University of Washington, Seattle, WA
11Center for Translational & Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY
12Cell Circuits Program, Broad Institute, Cambridge MA
13Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA
14Department of Pathology, University of Washington, Seattle, WA
15Department of Pathology, Stanford University, Stanford, CA
16Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
17Department of Psychiatry, Washington University School of Medicine, St. Louis, MO
18Ronald M Loeb Center for Alzheimer’s Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY
19Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ
20Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA
21Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
22Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
23Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
24UK Dementia Research Institute at UCL, London, UK
25Kaiser Permanente Washington Health Research Institute, Seattle, WA
26Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI
27Department of Neurology, the Johns Hopkins University School of Medicine, Baltimore, MD

*Data used in preparation of this article were obtained from the Alzheimer’s Disease

Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within
the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:


*To whom correspondence should be addressed: Timothy J Hohman, PhD, Vanderbilt Memory & Alzheimer’s Center, Vanderbilt University Medical Center, 1207 17th Avenue S, Nashville, TN 37212. E-mail: Timothy.J.Hohman@vumc.org. Phone: 615-343-8429.

Acknowledgements

This research was supported in part by K01 AG049164, R21 AG05994, K12 HD043483, K24 AG046373, HHSN311201600276P, S10 OD023680, R01 AG034962, R01 HL111516, R01 NS100980, R01 AG056534, P30 AG10161, RF1 AG15819, R01 AG17917, R01 AG30146, R01 AG019085, R01 AG15819, R01 AG30146, R01 AG027161, R01 AG021155, R01 AG037639, U01 AG46152, U01 AG006781, U01 AG032984, U01 HG004610, U01 HG006375, U24 AG021886, U24 AG041689, R01 AG044546, P01 AG003991, RF1 AG053303, R01 AG035083, R01 NS085419, UL1 TR000445, KL2 TR000446, TL1 TR000447, S10 OD023680, and the Alzheimer’s Association (NIRG-11-200110), further supported in part by the Intramural Research Program, NIA, NIH and the Vanderbilt Memory & Alzheimer’s Center. YD was supported by an NIMH training grant (T32MH014877). Support for PDJ was provided by R01 AG048015. HZ is a Wallenberg Academy Fellow and is further supported but the Swedish and European Research Councils and the UK Dementia Research Institute. KB holds the Torsten Söderberg professorship at the Royal Swedish Academy of Sciences.

The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD,
PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Grabowski, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD).

Samples from the National Cell Repository for Alzheimer’s Disease (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible; Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689-01).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Abstract

Autopsy measures of Alzheimer’s disease (AD) neuropathology have been leveraged as endophenotypes in previous genome-wide association studies (GWAS). However, despite evidence of sex differences in AD risk, sex-stratified models have not been incorporated into previous GWAS analyses. We looked for sex-specific genetic associations with AD endophenotypes from 6 brain bank data repositories. The pooled dataset included 2701 males and 3275 females, the majority of whom were diagnosed with AD at autopsy. Sex-stratified GWAS were performed within each dataset and then meta-analyzed. Loci that reached genome-wide significance (p<5x10^{-8}) in stratified models were further assessed for sex interactions. Additional validation was performed in independent datasets leveraging cognitive, neuroimaging, and cerebrospinal fluid endophenotypes, along with age-at-onset data. Outside of the APOE region, one locus on chromosome 7 (rs34331204) showed a sex-specific association with neurofibrillary tangles among males (p=2.5x10^{-8}) but not females (p=0.85, sex-interaction p=2.9x10^{-4}). In validation analyses, rs34331204 was also associated with hippocampal volume, executive function, and age-at-onset only among males. Expression quantitative trait loci results from brain highlight BZW2 and ANKMY2 as candidate genes at this locus. These results implicate a novel locus that confers male-specific protection from tau pathology and highlight the value of assessing genetic associations in a sex-specific manner.

Keywords: Alzheimer’s disease; neuropathology; sex difference; amyloid; tau; GWAS
1. Introduction

Two-thirds of Alzheimer’s disease (AD) cases are female (Mielke et al., 2014; Mazure and Swendsen, 2016) and emerging evidence has highlighted notable sex differences in AD risk (Altmann et al., 2014; Neu et al., 2017; Buckley et al., 2018), presentation (Barnes et al., 2005; Apostolova et al., 2006; Hua et al., 2010; Hohman et al., 2018), and progression (Barnes et al., 2005; Koran et al., 2017). Notably, the Apolipoprotein E (APOE) gene which is the strongest genetic risk factor for AD shows a stronger association among females compared to males, particularly between 65 and 75 years of age (Neu et al., 2017). Despite the growing evidence of sex differences in AD neuropathology and the genetic drivers of AD neuropathology (Deming et al., 2018), limited work has systematically explored sex-specific genetic associations with AD neuropathology across the genome.

Autopsy measures of neuropathology, including the Consortium to Establish a Registry for Alzheimer’s disease (CERAD) neuritic plaque staging and Braak neurofibrillary tangle staging, have been leveraged in previous GWAS to identify novel genetic loci for AD that were not identified in case/control analyses (Beecham et al., 2014). These endophenotypes provide an invaluable opportunity to better understand the underlying disease process by providing biological measures that are more proximal to gene function. Moreover, these metrics provide ideal outcomes for the investigation of sex-specific analyses because identified associations will highlight points along the disease cascade where sex differences begin to emerge.

This study leverages 6 autopsy cohorts to assess sex-specific genetic associations with AD neuropathology. First, we perform a sex-stratified GWAS in 5,976
participants with autopsy measures of neuritic plaques and neurofibrillary tangles. Second, we validate observed sex-specific associations leveraging complementary biomarker data from independent datasets. Our central hypothesis is that certain genetic factors act in a sex-specific manner to drive the neuropathological presentation of AD. The identification of sex-specific effects will advance our understanding of the genetic architecture of AD and clarify the underlying pathways that contribute to AD neuropathology.

2. Materials and methods

2.1 Participants

Participants were drawn from a previously published genome-wide neuropathology analysis (Beecham et al., 2014) which includes detailed descriptions of the six well-characterized cohorts used in this study. Studies included the National Institute on Aging Late-Onset Alzheimer’s Disease Family Study (LOAD), Mayo Clinic (Mayo), the Adult Changes in Thought (ACT) study, the National Alzheimer’s Coordinating Center (NACC), the Religious Orders Study and Rush Memory and Aging Project (ROS/MAP), and the Translational Genomics Research Institute (TGEN). Additionally, we excluded individuals younger than 60 or missing a clinical dementia diagnosis. All participants agreed to brain donation and were evaluated at each site.

2.2 Quantification of Neuropathology Outcomes

Autopsy measures of neurofibrillary tangles (Braak staging) and neuritic plaques (CERAD score) were collected in each cohort and harmonized for a previously published GWAS (Beecham et al., 2014). Thal stage was not collected in all studies so
was not included in our staging definitions. Both measures were analyzed as binary outcomes. Binary neuritic plaque (NP) status was defined based on established neuropathological criteria for AD (Hyman et al., 2012) whereby a CERAD score of “none” or “sparse” was considered “NP negative”, and “moderate” or “frequent” was considered “NP positive”. Similarly, the binary neurofibrillary tangles (NFT) status was defined whereby Braak stages none, I, or II were considered “NFT negative” and stages III, IV, V, or VI were considered “NFT positive” (Hyman et al., 2012).

### 2.3 Quantification of Clinical, Structural, and Laboratory Biomarkers of AD

Validation analyses were performed using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and using cerebrospinal fluid (CSF) data from a previously published GWAS (Deming et al., 2018). We leveraged preprocessed ADNI amyloid positron emission tomography (PET) data, specifically baseline mean cortical florbetapir uptake calculated from six established regions of interest, normalized to whole cerebellum (Landau et al., 2012). Episodic memory and executive function composite scores were calculated in ADNI previously (Crane et al., 2012; Gibbons et al., 2012). Hippocampal and intracranial volumes were captured using MRI and quantified using FreeSurfer as previously described (Mormino et al., 2009). Quantification of CSF levels of Aβ42, total tau (t-tau), and phosphorylated tau (p-tau) were performed independently in seven cohorts (ADNI, Mayo, University of Pennsylvania, University of Washington, BIOCARD, Knight ADRC, and a multi-center AD study from Sweden) as described in a previous GWAS publication (Deming et al., 2017). Finally, age-at-onset data from a previous GWAS analysis (Huang et al., 2017) was used to evaluate sex-specific associations with AD progression.
2.4 Measures of Gene Expression and Semi-Quantitative Neuropathology in ROS/MAP Brain Tissue

Gene expression data from ROS/MAP were obtained through the Accelerating Medicines Partnership AD project. RNA expression was processed from frozen, manually dissected sections of dorsolateral prefrontal cortex (PFC) tissue as previously described (Lim et al., 2014). For the present analyses, low abundance genes (expressed in <10% of the cohort) were removed. Semi-quantitative measures of AD neuropathology were measured using immunohistochemistry and quantified by image analysis and stereology (Bennett et al., 2012a; Bennett et al., 2012b). Tangle density was quantified with AT8 antibody across 8 regions of the brain (Bennett et al., 2012a; Bennett et al., 2012b).

2.5 Genotyping and Quality Control

Genome-wide genotyping was performed by each study on a variety of genotyping platforms. Imputation was performed on the University of Michigan Imputation Server in all datasets using the HRC r1.1.2016 reference panel, SHAPEIT phasing, and the EUR (European) population. Prior to imputation, all genotype data were processed through the same quality control protocol, including removing single nucleotide polymorphisms (SNPs) that had a poor call rate (<98% calls on Illumina platforms, <95% calls on Affymetrix platforms) or outside of Hardy-Weinberg equilibrium (p<1x10^-6). Samples were limited to those of European-descent and were excluded for sex inconsistency or cryptic relatedness (Pihat>0.4). Following imputation, SNPs with MAF>0.01 and imputation R^2>0.3 were retained for subsequent analysis.
2.6 Statistical Analyses

Sex differences in clinical and demographic characteristics were evaluated using an independent samples t-test for continuous variables and a χ² test for categorical variables in R (https://www.r-project.org/). Sex-stratified analyses of NFT and NP were performed using logistic regression in PLINK (Version 1.9, https://www.cog-genomics.org/plink/1.9). Analyses were performed within each cohort separately, used additive coding, and covaried for age at death. Fixed-effects meta-analysis was performed using GWAMA (http://www.geenivaramu.ee/en/tools/gwama) (Mägi and Morris, 2010). Results were limited to SNPs that were present in at least three of the six cohorts. The threshold for statistical significance was set at the standard GWAS level of p=5x10⁻⁸. All significant sex-stratified effects were assessed for sex x SNP interactions. Sex-stratified Miami plots were generated using EasyStrata (version 16.0) (Winkler et al., 2014). Genomic inflation factors for the GWAS analyses ranged from λ=0.99-1.04 (Supplementary Fig. 1). SNP annotation was performed using ANNOVAR (version 2018Apr16). Forest plots were generated using the R package Metafor.

SNPs with putative sex-specific associations with neuropathology were further assessed for correlation with baseline episodic memory, executive function, amyloid PET, hippocampal volume, and CSF levels of Aβ42, t-tau, and p-tau using linear regression in R, covarying for baseline age. Hippocampal volumes were normalized by intracranial volume using established procedures (Voevodskaya et al., 2014). Finally, putative SNPs were also evaluated in sex-specific associations with age-at-onset using data from a previously published survival analysis of AD (Huang et al., 2017).
2.7 Expression Quantitative Trait Analysis

SNPs that showed a sex-specific association were further assessed for expression quantitative trait locus (eQTL) associations using data from Braineac (http://caprica.genetics.kcl.ac.uk/BRAINEAC/). Correction for multiple comparisons was completed using the false discovery rate (FDR) procedure, correcting for the total number of gene-tissue combinations.

Significant eQTL genes were further assessed for sex-specific associations with AD neuropathology leveraging gene expression data from ROS/MAP. Sex-stratified and sex-interaction analyses were completed using linear regression covarying for age at death. Tangle load was square-root transformed to better approximate a normal distribution.

3. Results

A total of 2701 males and 3275 females across six independent autopsy datasets were analyzed. In general, females were older than males (males: 79±9 years, females: 81±9 years, p<0.001) and were more frequently AD cases (males: 68%, females: 71%, p=0.02), APOE-ε4 carriers (males: 49%, females: 46%, p=0.03), and NP- and NFT-positive individuals (males: 72% and 77%, females: 76% and 85%, p-values<0.01) than males. Participant characteristics by cohort are presented in Supplementary Table 1.

In the sex-stratified GWAS analysis of NFT, one SNP (rs34331204; Fig. 1; Supplementary Fig. 2) outside of the APOE locus reached genome-wide significance in males (β=-0.720; p=2.48x10⁻⁸) but not in females (β=-0.027; p=0.85). Furthermore, rs34331204 showed an interaction with sex on NFT (β=0.71; p=2.93x10⁻⁴), with the
minor allele was associated with a lower risk of NFT positivity in males (Fig. 2). It is notable that this association did not meet genome-wide significance in the larger sex-combined sample (β=-0.39; p=2.63x10^-5) and, thus, may have been overlooked if we did not explicitly model sex. No associations reached genome-wide significance in the sex-stratified GWAS analysis of NP (Supplementary Fig. 3). The top meta-analysis results from sex-stratified GWAS of NP and NFT are presented in Supplementary Tables 2-5.

The putative sex-specific locus was then assessed for associations with cognition, amyloidosis, neurodegeneration, and age-at-onset using publicly available data sources. Results are presented in Table 1. The sex-specific association with NFT (rs34331204) showed a comparable male-specific association with executive function performance and hippocampal volume (Fig. 2), with mixed evidence of a sex difference in the age-at-onset analysis. No sex-specific associations with CSF tau or p-tau were observed.

Lastly, we used eQTL mapping in Braineac to identify candidate genes within the rs34331204 locus and analyzed expression of these genes in brain tissue. Significant eQTL associations (FDR-corrected aveALL p-value<0.05 in Braineac) were seen for eight genes (BZW2, TSPAN13, AGR3, ANKMY2, LRRC72, AGR2, ISPD, and AHR; Supplementary Table 6). Two of these genes were not highly expressed in ROS/MAP PFC (AGR3 and LRRC72), so we assessed six genes for sex-specific associations with tau load (Table 2). Surprisingly, BZW2 and ANKMY2 showed evidence of female-specific associations with tau load (p-values<0.002), but no male-specific associations or sex-interactions were observed.
4. Discussion

The present manuscript evaluated sex-specific genetic associations with AD neuropathology measured at autopsy. Results implicate one novel genetic locus, rs34331204 on chromosome 7 proximal to BZW2, that is associated with neurofibrillary tangles only among males. Additional evidence of a male-specific neuroprotective effect was observed in validation analyses in which the minor allele of rs34331204 was also associated with larger hippocampal volume, better executive function, and a later age-at-onset among males. It is important to note that the association between rs34331204 and NFT fell below the threshold of genome-wide significance when males and females were combined, and sex was simply included as a covariate in a post-hoc analysis, highlighting the utility of sex-stratified analyses in uncovering novel potential disease loci.

There are a number of potential candidate genes within the associated locus, and rs34331204 was a strong eQTL for eight of them, complicating the picture. Among the implicated genes, ANKMY2 and BZW2 showed some weak evidence of association with tangle burden. It should be noted that the gene expression effects of these two genes were observed among females rather than males, counter to the male-specific SNP effects. The female-specific gene expression association may suggest that there is a male-specific eQTL effect (which we could not test from available data as Braineac does not offer results stratified by sex), or that these two genes are not the functional genes driving the male-specific association. However, given the sex x gene expression interaction was not significant, and there are more females than males in the ROS/MAP
expression sample, it is probably safest to assume the gene expression effect is not sex-specific while the SNP effect is male-specific.

Both implicated genes, *ANKMY2* and *BZW2*, are interesting candidates. *BZW2* is a basic leucine zipper protein with a known role in cell proliferation through the Akt/mTOR pathway, particularly in cancer (Cheng et al., 2017). Associations between dual leucine zipper proteins and neurodegenerative disease have been reported in the literature recently (Le Pichon et al., 2017). While no functional association between *BZW2* and neurodegeneration has been reported to date, it is notable that a SNP within *BZW2* (rs58370486) previously showed an association with cognitive decline in AD (p=6x10^{-11}) (Sherva et al., 2014). The protein product of *ANKMY2* has been shown to interact with FKBP38 in the mouse brain, regulating the Sonic hedgehog signaling pathway (Saita et al., 2014), but FKBP38 also acts as a BCL2 chaperone which has been implicated in an apoptotic pathway downstream of amyloidosis (Kudo et al., 2012). However, *ANKMY2* has not been directly implicated in AD previously. The present results suggest future functional and fine-mapping work in the rs34331204 region should focus on potential sex-specific effects.

This study had multiple strengths including the large sample size gathered across multiple cohort studies, the comprehensive validation analyses in independent studies using complementary endophenotypes of amyloidosis, tau, neurodegeneration, and cognition, and the functional assessment of gene expression in prefrontal cortex tissue providing evidence of sex-specific associations at the gene level. However, there were also important limitations, including the noted age difference between males and females, the high percentage of AD cases, and the high percentage of *APOE* ε4 carriers.
within the leveraged datasets. These limitations leave open the strong possibility that additional sex-specific genetic loci for amyloid and tau pathology, particularly in the preclinical stages of disease, were probably undetected in our analyses. Further, the present analyses were restricted to individuals of European ancestry, leaving open the possibility that findings may not extend to other racial or ancestral backgrounds. Future work extending to datasets with more cognitively normal individuals and a more representative sample will be important to better understand sex-specific associations across the spectrum of normal aging and dementia. Nevertheless, our results highlight a novel sex-specific candidate locus for AD and demonstrate the utility of incorporating sex considerations into genetic models of disease.

5. References


6. Potential Conflicts of Interest

Dr. Larson reports royalties from UpToDate. Dr. Schneider reports personal fees from Avid Radiopharmaceuticals, personal fees from Navidea Biopharmaceuticals, outside the submitted work. Dr. Zetterberg has served at advisory boards of Eli Lilly, Roche Diagnostics and Pharmasum Therapeutics and is one of the founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr. Blennow has served at advisory boards of Alzheon, BioArctic, Eli Lilly, IBL International, Fujirebio, Merck, and Roche Diagnostics and is one of the founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.
7. Tables

Table 1. Associations between rs34331204 and Relevant Alzheimer’s Disease Endophenotypes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>N</th>
<th>Males</th>
<th></th>
<th>Females</th>
<th></th>
<th>Sex-Interaction</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Beta</td>
<td>P</td>
<td>Beta</td>
<td>P</td>
<td>Beta</td>
<td>P</td>
</tr>
<tr>
<td>CSF Tau</td>
<td>2926</td>
<td>0.006</td>
<td>0.69</td>
<td>-0.009</td>
<td>0.58</td>
<td>-0.013</td>
<td>0.55</td>
</tr>
<tr>
<td>CSF P-tau</td>
<td>2759</td>
<td>-0.002</td>
<td>0.89</td>
<td>-0.011</td>
<td>0.47</td>
<td>-0.010</td>
<td>0.63</td>
</tr>
<tr>
<td>Episodic Memory</td>
<td>1182</td>
<td>0.104</td>
<td>0.14</td>
<td>0.038</td>
<td>0.73</td>
<td>-0.063</td>
<td>0.62</td>
</tr>
<tr>
<td>Executive Function</td>
<td>1182</td>
<td><strong>0.266</strong></td>
<td><strong>0.0010</strong></td>
<td>-0.016</td>
<td>0.88</td>
<td><strong>-0.283</strong></td>
<td><strong>0.039</strong></td>
</tr>
<tr>
<td>Hippocampal Volume</td>
<td>1086</td>
<td><strong>252.17</strong></td>
<td><strong>0.014</strong></td>
<td>-33.18</td>
<td>0.80</td>
<td>-284.70</td>
<td>0.09</td>
</tr>
<tr>
<td>Age of Onset in ADGC</td>
<td>17603</td>
<td>-0.091</td>
<td>0.052</td>
<td>0.043</td>
<td>0.27</td>
<td><strong>0.136</strong></td>
<td><strong>0.022</strong></td>
</tr>
<tr>
<td>Age of Onset in GERAD</td>
<td>3552</td>
<td>0.076</td>
<td>0.47</td>
<td>0.077</td>
<td>0.35</td>
<td>0.015</td>
<td>0.91</td>
</tr>
</tbody>
</table>

*Boldface* font signifies p<0.05.

Table 2. Associations between Tau Load and rs34331204 cis Gene Expression in Brain Tissue

<table>
<thead>
<tr>
<th>Gene</th>
<th>Males</th>
<th></th>
<th>Females</th>
<th></th>
<th>Sex-Interaction</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Beta</td>
<td>P</td>
<td>Beta</td>
<td>P</td>
<td>Beta</td>
<td>P</td>
</tr>
<tr>
<td>AGR2</td>
<td>-2.069</td>
<td>0.59</td>
<td>-0.824</td>
<td>0.60</td>
<td>1.263</td>
<td>0.76</td>
</tr>
<tr>
<td>AHR</td>
<td>-0.233</td>
<td>0.42</td>
<td>0.189</td>
<td>0.29</td>
<td>0.420</td>
<td>0.21</td>
</tr>
<tr>
<td>ANKMY2</td>
<td>-0.037</td>
<td>0.22</td>
<td>-0.078</td>
<td>9.93x10^-4</td>
<td>-0.041</td>
<td>0.28</td>
</tr>
<tr>
<td>BZW2</td>
<td>-0.027</td>
<td>0.48</td>
<td>-0.093</td>
<td>2.02x10^-3</td>
<td>-0.064</td>
<td>0.18</td>
</tr>
<tr>
<td>ISPD</td>
<td>-0.395</td>
<td>0.18</td>
<td>-0.537</td>
<td>0.018</td>
<td>-0.145</td>
<td>0.70</td>
</tr>
<tr>
<td>TSPAN13</td>
<td>-0.001</td>
<td>0.94</td>
<td>-0.010</td>
<td>0.049</td>
<td>-0.010</td>
<td>0.30</td>
</tr>
</tbody>
</table>

Gene expression data was collected from prefrontal cortex tissue of participants from the Religious Orders Study/Memory and Aging Project (Males: n=213, Females: n=380).
8. Figure Legends

**Fig. 1. Sex-Stratified Genome-Wide Association Results for Tangle Positivity. (a)**
Miami plot illustrating neurofibrillary tangle positivity genome-wide association results stratified by males and females. Male findings are plotted in blue and grey on the top and female results are plotted in pink and grey at the bottom. The red lines at the top and bottom represent the genome-wide threshold for statistical significance (p<5x10^{-8}). Regional association plots for the rs34331204 association with neurofibrillary tangle positivity within (b) males and (c) females.

**Fig. 2. Male-Specific SNP (rs34331204) Associated with Protection from Neurofibrillary Tangles Also Relates to Hippocampal Volume and Executive Function.** Sex-specific association of rs34331204 with neurofibrillary tangles (Panel A), hippocampal volume (Panel B), and executive function (Panel C). Within each panel, males are presented on the left and females are presented on the right. Outcomes are presented on the y-axes. Bar colors represent rs34331204 genotype. Homozygous carriers of the A allele are presented in dark green on the left, heterozygotes in light green in the middle, and homozygous carriers of the C allele in the lightest green on the right. A neuroprotective effect of the rs34331204 C allele is observed among males, but not females.